July 19, 2022
Life Sciences
  • House representatives called on the Department of Health and Human Services (HHS) to penalize drugmakers that have lowered or eliminated price breaks through the federal 340B Drug Discount program. In a letter, the group of 181 lawmakers said, “vulnerable communities, federal grantees, and safety net health care providers are deprived of resources Congress intended to provide.” At this point, 18 top drug companies have cut discounts or limited the number of contract pharmacies that are allowed to distribute their products. Several have already been warned by HHS’ inspector general that penalties could be levied if discounts aren’t reinstated. (Article here)